Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a PROTEASE polypeptide, or fragment thereof, and measuring a compound-PROTEASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including cleaved protease substrate and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of PROTEASE expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimer's disease.

Abstract: The present invention relates to cell and animal models for a disease condition and in particular to an animal model which can function as a model for neurodegenerative diseases, such as Alzheimers.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a KINASE polypeptide, or fragment thereof, and measuring a compound-KINASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including phosphorylated kinase substrate and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of KINASE expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimer's disease.

Abstract: A method for identifying compounds that inhibit aberrant amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a LIGASE polypeptide, or fragment thereof, and measuring a compound-LIGASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of LIGASE DNA expression agents or LIGASE agonists, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a SPHK polypeptide, or fragment thereof, and measuring a compound-SPHK property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including phosphorylated kinase substrate and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of SPHK expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimer's Disease.

Abstract: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.